

INTERIM REPORT

January to June 2011



QUALITY AND GROWTH.

-
- VITA 34 Slovakia has been founded
 - New Sales Cooperation with MVZ synlab Leverkusen
 - Revenue Increase in first half-year
-

 **VITA 34**

CONSOLIDATED KEY FIGURES

| | | 04/01 – 06/30/2011 | 04/01 – 06/30/2010 | 01/01- 06/30/2011 | 01/01- 06/30/2010 |
|-------------------------------------|--------|-----------------------|-----------------------|----------------------|----------------------|
| STEM CELL PREPARATIONS | | | | | |
| Umbilical cord blood storages | Number | 2,287 | 2,675 | 4,477 | 5,152 |
| PROFIT / LOSS | | | | | |
| Revenues | EUR k | 4,058 | 4,109 | 7,772 | 7,600 |
| Gross profit | EUR k | 2,379 | 2,631 | 4,571 | 4,868 |
| EBITDA | EUR k | -25 | 381 | -160 | 666 |
| EBIT | EUR k | -218 | 24 | -628 | 184 |
| Period result | EUR k | -151 | -76 | -449 | 189 |
| | | | | 06/30/2011 | 06/30/2010 |
| BALANCE SHEET / CASH FLOW | | | | | |
| Total assets | EUR k | | | 33,556 | 36,753 |
| Equity | EUR k | | | 18,369 | 18,931 |
| Equity ratio | % | | | 54.7 | 51.5 |
| Liquid funds | EUR k | | | 2,254 | 4,527 |
| Capital expenditures* | EUR k | 216 | 355 | 463 | 571 |
| Depreciation* | EUR k | 243 | 357 | 468 | 482 |
| Cash flow from operating activities | EUR k | 409 | 285 | -2,031 | -309 |
| EMPLOYEES | | | | | |
| Employees (as of June 30) | Number | | | 136 | 131 |
| Personnel expenditures | EUR k | | | 2,981 | 2,648 |

* Information for tangible and intangible assets

CONTENTS

| | PAGE |
|---|-------------|
| LETTER TO THE SHAREHOLDERS | 4 |
| GROUP INTERIM REPORT | |
| 1 Summary | 6 |
| 2 Revenue and Profit Situation | 6 |
| 3 Financial and Asset Situation | 7 |
| 4 Investments | 9 |
| 5 Employees | 9 |
| 6 VITA 34 on the Capital Market | 9 |
| 7 Risks and Market Opportunities | 10 |
| 8 Outlook | 11 |
| 9 Declaration of Legal Representatives | 11 |
| CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS | |
| 1 Condensed Consolidated Statement of Income | 12 |
| 2 Condensed Consolidated Statement of Comprehensive Income | 13 |
| 3 Condensed Consolidated Statement of Financial Position | 14 |
| 4 Condensed Consolidated Statement of Changes in Group Equity | 16 |
| 5 Condensed Consolidated Statement of Cash Flows | 18 |
| NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS | 20 |
| BOARD MEMBERS | 24 |
| FINANCIAL CALENDAR AND CREDITS | 25 |

LETTER TO THE SHAREHOLDERS

Dear Shareholders,

The first half-year of 2011 was economically challenging and medically successful for VITA 34. To date, stem cells from umbilical cord blood that was stored at VITA 34 has been used three times in the current year for use in therapies in Germany and abroad. The meaningfulness of the private storage of umbilical cord blood as a medically important preventative service has once again been proven in this way. VITA 34 remains the only private umbilical cord blood bank in Germany that has been able to demonstrate tangible medical applications to date. A bulwark for the successful application of preparations are also the high quality standards of VITA 34 and the comprehensive official permits for the use of the umbilical cord blood we prepare in different medical fields. Altogether, there have been a total of 18 applications. The therapy spectrum here ranges from the treatment of what is known as cerebral palsy via the treatment of brain damage to the use in the treatment of Type 1 diabetes within the context of a study. The increasing use of umbilical cord blood in stem cell therapy and in regenerative medicine should lead long-term to a clear increase in the acceptance of storage. However, it is unclear at what point along the time line this effect will take hold.

Correspondingly, VITA 34 further increased and adjusted marketing and sales activities in the first half-year 2011, in order to open up additional customer target groups with an existing basic acceptance of the storage of umbilical cord blood. In this context, new tailored pricing models such as "Vita 34 direkt" have been developed. This offer combines an initial price of EUR 690 for the storage with a monthly storage fee of EUR 8 and is, therefore, less capital intensive for expecting parents at the time of birth. Thus, this is a meaningful addition to the existing product family of Vita 34 Klassik, Vita 34 Max and VITApplusSpende [VITA plus Donation].

We also expect positive sales impetus from a cooperation with MVZ synlab Leverkusen GmbH, which will exist as of July 2011. It belongs to synlab Holding GmbH, one of the largest laboratory service providers in Germany, with more than 100 locations, primarily in western Germany. After a test phase, the plan is to expand cooperation. This will open up additional sales locations for VITA 34. Surveys of customers have shown that regional proximity is an important factor for the storage decision. It is not without reason, for example, that the storage rates are above-average around the company's headquarters in Leipzig. VITA 34 is fulfilling this need for regional presence indirectly via the cooperative sales efforts. The compensation model with synlab, here, is exclusively variable, such that fixed cost burdens for VITA 34 are avoided.

The additional measures in Marketing and Sales have by their nature not yet had an effect on the first half-year numbers. The period was characterized economically by an unchanging reticence with regard to expenditures for preventative services. This was a trend that could be observed in the entire industry. The at best stagnating storage figures for autologous umbilical cord blood in Germany have been accompanied by the complete elimination of new allogenic storages for the North German Bone Marrow and Stem Cell Registry, NKR. NKR cannot provide any financial resources for new storages at the moment.

In the Spanish market, the consequences of the economic crisis and the high level of competition intensity in the industry influenced the business development of our subsidiary, Secuvita, S. L. VITA 34 indirectly held a total of 88 percent of the shares in Secuvita, S. L. as of June 30, 2011. Our plans for Spain have not been completely fulfilled due to these peripheral conditions. These developments were not fully compensated for by the positive trend in market such as Italy.



Here, the storage figures showed a dynamic development. In the reporting period VITA 34 also founded a one-hundred percent subsidiary in Slovakia. The market entry into this country is being undertaken with the same partner that VITA 34 is working together with successfully in Slovenia. VITA 34 Slovakia is intended to provide a positive contribution to profits within several quarters.

The number of stored umbilical cord preparations in the first half-year of 2011 was 4,477 and was, therefore, below the value of 5,152 in the prior year's period. Revenues, on the other hand, of EUR 7.8 million exceeded the prior years level of EUR 7.6 million. Here, it should be taken into consideration that in the first half-year of 2010 the revenues of the Spanish subsidiary Secuvita, S. L. were not consolidated over the entire period. The profit figures in the first half-year 2011 were still under those of the prior year's period. EBIT was EUR -0.6 million following EUR 0.2 million and the net profit was EUR -0.4 million as compared with EUR 0.2 million. The equity capital quote on the other hand, rose from 51.5 percent to 54.7 percent.

In the second half-year of 2011 we expect an increase in revenues and a positive result. For the entire year, revenues should be attained that at least equal those of the prior year.

With regard to profit we expect to be in the black for the full year 2011. The medium-term goal of VITA 34 is renewed invigoration of growth. An expansion of the value chain in the field of healthcare could present itself as a sensible option for VITA 34 in this regard.

The Management Board is aware that the corresponding operative successes for the basis for a positive development of the VITA 34 stock price – its development in the first half-year of 2011 is not considered satisfactory. We will use the potential offered by our positioning as the most experienced private umbilical cord blood bank in the German-speaking countries, in order to achieve improvement. Moreover, we are convinced that in the coming months, as well, the umbilical cord blood preparations of VITA 34 will be used in the treatment of severe diseases and in regenerative medicine meaningfully, and they will thus help people.

Leipzig, July 18, 2011

Dr. med. Eberhard F. Lampeter
CEO

Jörg Ulbrich
CFO

GROUP INTERIM REPORT

01/01 to 06/30/2011

1 SUMMARY

VITA 34 offers the collection, preparation and storage of umbilical cord blood as a preventative medical service. As the first private umbilical cord blood bank in Europe, the company has a great deal of experience in the entire process chain, both for autologous as well as for allogenic use. Adult stem cells collected from umbilical cord blood are characterized by the fact that they are removed at the earliest possible point in time and, therefore, have particularly great potential. As compared with bone marrow stem cells there are greater possible uses than originally presumed. Stem cells are used in numerous therapies of severe diseases and in regenerative medicine.

VITA 34 is by far the largest umbilical cord blood bank in the German-speaking countries, with more than 82,000 stored umbilical cord blood preparations. VITA 34 services are offered in various configurations in additional European countries. Storages are performed for customers from Spain, Italy, Austria, Switzerland and Slovenia. With the founding of VITA 34 Slovakia in the first half-year of 2011, umbilical cord blood preparations from Slovakia will also be stored in Leipzig in the future. The foreign activities contribute to filling the capacities of VITA 34 in Leipzig.

Expecting parents can select different service and price offerings at VITA 34, all at the highest level of quality. Apart from the existing products Vita 34 Klassik, Vita 34 max and VITaplusSpende [Vita plus Donation] there is now also an attractive online offering: Vita 34 direkt. This provides expecting parents with the option of searching for information on the VITA 34 service package and entering into the contracts commensurate with their individual service wishes via the Internet. This offering, which entails a lower entry price and an ongoing monthly fee of EUR 8, is only being offered in Germany initially.


Altogether, the business development of VITA 34 is mainly determined by how trustworthy and credible the storage of umbilical cord blood is perceived to be amongst the general public. Therefore, it is an important objective of VITA 34 to increase the acceptance and impart the meaningfulness of the provisional storage of umbilical cord blood. The dialog primarily with opinion leaders in healthcare, physicians and midwives makes an important contribution. This is why VITA 34 is active in basic research as well as applied research.

2 REVENUE AND PROFIT SITUATION

The number of stored stem cell preparations in Q2 2011 was 2,287 and, therefore, 4.4 percent higher than Q1 which had 2,190 storages. In Q2 2010 2,675 stem cell preparations were stored at VITA 34. In all, in the first half year of 2011 the number of storages declined slightly from 5,152 in the corresponding period the previous year to 4,477. No new umbilical cord blood preparations for German Cord Blood Bank [Deutsche Nabelschnurblutbank] were stored in the first half of 2011, since NKR cannot provide any financial resources for this at the moment. The storages for our Italian Partner Sorgente, S.r.L. showed a positive development.

Revenues, which trail storages by one to two months, were at the same level in Q2 2011 with EUR 4.1 million as they were in Q2 of the prior year. In the first half-year of 2011 they were EUR 7.8 million as compared to EUR 7.6 million in the prior year's period.

The gross profit from sales in Q2 2011 of EUR 2.4 million was slightly under the value of the prior year's level. In the first half of the year the gross profit declined slightly from EUR 4.9 million in the prior year to EUR 4.6 million. Here, it should be taken into consideration that Secuvita, S. L. was fully consolidated in 2011, whereas only one and a half months were incorporated in the prior year's period.



The marketing and sales expenditures dropped in Q2 significantly to EUR 1.8 million following EUR 1.9 million the prior year. In all, expenditures for marketing and sales increased to EUR 3.7 million in the first half-year of 2011, following EUR 3.6 million in the prior year's period. In addition, administrative costs were lower in Q2 2011 at EUR 0.8 million following EUR 0.9 million the year before. In the first half-year they increased from EUR 1.4 million to EUR 1.6 million. For the most part, the cost increases in the first half-year of 2011 were the result of the full consolidation with Secuvita, S. L., as well as from necessary depreciations of plant and equipment. Increases in efficiencies in sales and planned savings in administration reduced the costs on Q2 2011.

The earnings before interest and taxes, EBIT, were EUR -218k in Q2, following EUR 24k the prior year. In the first half-year of 2011 the EBIT was EUR -628k. A year before it was EUR 184k. In Q2 the financial result was EUR -49k, following EUR -23k the prior year. The financial result in the first half-year was EUR -38k as compared with EUR 32k the year before.

In accordance with IFRS there was a tax credit of EUR 116k in Q2, as compared with a tax burden of EUR -77k in the corresponding prior year's period. There was a positive tax effect of EUR 217k in the first half of 2011 arising from deferred taxes following EUR -27k in the prior year's period.

In all the period result in Q2 2011 was EUR -0.2 million, following EUR -0.1 million the prior year. Thus, the period profit/loss for the first half-year of 2011 was EUR -0.4 million, in the wake of EUR 0.2 million in the prior year's period.

3 FINANCIAL AND ASSET SITUATION

Financial Situation

Liquid funds decreased by EUR 2.7 million to EUR 2.3 million at the end of the first half-year 2011, down from EUR 5.0 million at year's end 2010. As compared with Q1 2011 liquid funds in the reporting period increased by EUR 0.2 million. A major part of the change in cash was the result of operating activities. Following a cash flow from operating activities of EUR -2.4 million in Q1 2011, in Q2 a positive cash flow from operating activities of EUR 0.4 million was achieved. In the first half year of 2011 the operating cash flow totaled EUR -2.0 million, following EUR -0.3 million the prior year. The reduction in liabilities in the first half-year of 2011 had a negative effect of EUR 2.4 million.

The cash flow from investing activities was EUR 1.1 million in the first half year of 2011. Altogether, EUR 1.5 million of this was attributable to the sale of current financial investments in the first half-year. The cash flow from financing activities was negative in the first half year of 2011 at EUR -0.3 million.

Assets

Unchanged, VITA 34 International AG has a solid balance sheet structure. As of June 30, 2011, the equity ratio was some 55 percent and had increased slightly as compared to the status at the end of 2010 when it was 51 percent. The balance sheet total decreased to EUR 33.6 million as of June 30th, as compared to EUR 36.7 million at the end of 2010.

On the assets side Goodwill of EUR 13.4 million remained unchanged the largest item. It is comprised of the goodwill of the subsidiaries VITA 34 AG and Secuvita, S. L.


QUALITY. Already 18 umbilical cord blood preparations privately stored at VITA 34 were applied.


Due to a slight reduction in other receivables and assets, the current assets without liquid funds decreased from EUR 5.2 million at the end of 2010 to EUR 4.9 million as of June 30, 2011. Liquid funds decreased from EUR 5.0 million at year's end 2010 to EUR 2.3 million in the first half-year 2011. As of June 30, 2011 it comprised cash and bank deposits in the amount of EUR 2.4 million, minus an overdraft facility of EUR 0.1 million.

On the liabilities side of the balance sheet the equity as of June 30, 2011 was EUR 18.4 million and, thus, slightly under the year's end 2010 level of 18.8 million. The registered capital remained constant at EUR 2.6 million. The long-term liabilities without deferred income increased slightly in the first half of 2011 to EUR 4.9 million, following EUR 4.6 million at the end of 2010.

Deferred income increased in the first half-year of 2011 from EUR 6.9 million at year's end 2010 to EUR 7.3 million. This is where the storage fees for the stem cell preparations from umbilical cord blood paid by customers in advance are contained. The storage fees are dissolved linearly over the prepaid term.

The current liabilities without deferred income decreased significantly by EUR 3.4 million from EUR 6.4 million at the end of 2010 to EUR 3.0 million as of June 30, 2011. Here, other liabilities of EUR 3.1 million as of the end of 2010 were significantly reduced to EUR 0.9 million at the end of the first half-year 2011. Interest bearing loans were reduced from EUR 2.1 million at the end to 2010 to EUR 1.1 million at the end of June 2011.





4 INVESTMENTS

VITA 34 made investments in plant and material and intangible assets in the amount of EUR 0.2 million in Q2 2011. This amount corresponds to the one of the prior year's period. In the first six months of 2011 the investments totaled EUR 0.5 million and were, thus, at the level of the prior year, in which EUR 0.6 million was posted. The investments were mainly in pre-payments for process software in the IT department and in expanding the cryo and storage capacities at the company's headquarters in Leipzig. It is expected that there will be no significant change in investment activity in the coming quarter.

5 EMPLOYEES

On June 30, 2011 VITA 34 employed 136 employees and five trainees in either full or part-time positions. Six months before that there had been 147 employees.

As of June 30, 2011, some 44 percent of the VITA 34 employees were active in marketing and sales. This department was unchanged the by far largest share with 60 employees. In production and quality assurance VITA 34 had 47 and in the commercial department 29 employees.

6 VITA 34 ON THE CAPITAL MARKET

After ending the year 2010 at EUR 4.66 in trading on Xetra, the VITA share price reached its first half-year 2011 high of EUR 5.46 on April 15, 2011. Subsequently, the quotation showed a lateral movement around the EUR 4 mark and closed at EUR 3.93 on June 30, 2011. The initial growth was dampened by developments in the international markets, and especially by the weakness of industry-specific second-line stocks.

Corporate events that had a significant effect on the price of the VITA share were the publication of the 2010 financial results and the financial prognosis for 2011, the financial analysis of First Berlin, the statements VITA 34 International AG made in the Q1 2011 quarterly report and the founding of the one-hundred percent subsidiary VITA 34 Slovakia.

The analysts from First Berlin were convinced by these and other positive developments. In their UPDATE published on June 15, 2011, they again confirmed their evaluations concerning VITA 34 and its stock. In this report they evaluate the company as profitable and expect there to be a positive development of business. The target price for the VITA 34 International AG stock was again confirmed to be EUR 7.00.

In the first half-year of 2011 a total of 496,534 VITA shares were traded on all German exchanges, with an average volume of 3,941 share per day. The VITA share posted a significant increase in trading volume in Q2, with an average of 4,801 shares per day traded.

The German stock index DAX showed a remarkably positive development from year's end 2010 to the end of June 2011, despite the financial debt issues in Europe, the consequences of the natural catastrophe in Japan, as well as the weak economic development in the USA. According to the Euro am Sonntag [Euro On Sunday] the price/profit ratio in the period mentioned was 10.7 percent, and is considered to be very moderate, considering the 6.5 percent profit growth expected for 2011. However, the price potential of the exchanges was dampened worldwide by the increasing economic risks and uncertainties.

Both the CDAX as well as the Pharma & Healthcare Performance Index continued to show a positive development in the reporting period as compared with the beginning of the year. The VITA share followed the developments up to the beginning of June 2011, and unfortunately closed lower than the overall market at the end of June 2011.

GROWTH. VITA 34 has founded subsidiary in Slovakia.

The Management Board of VITA 34 will continue to keep communication with the capital markets at a commensurably high level. In Q2 already the company presented itself at the Munich Capital Market Conference, and conducted a corporate presentation with investors, analysts and journalists at the company's headquarters. Additional investor contacts are planned for Q3 and Q4. Consequently, VITA 34 will present at the German Equity Capital Forum of the Financial Community in November and publish the second edition of its Shareholder's Letter at the end of the year.

In ICF Kursmakler AG VITA 34 has a designated sponsor that ensures the liquidity of the shares as well as a close bid-offer spread in trading, thus increasing the attractiveness of the stock for investors. There were no changes in the fundamental shareholder structure: The percentage of VITA shares held by founders and management is now 15.1 percent. The largest single shareholder is the American health insurance company Independence Blue Cross with a share of 20.7 percent.

Landesbank Baden-Württemberg held 15.8 percent via its subsidiaries CFH Beteiligungsgesellschaft mbH (9.15 percent) and SBF Sächsische Beteiligungsfonds GmbH (6.68 percent) of VITA 34 International AG. Free-float according to the Deutsche Börse AG definition was 48.8 percent.

You will find additional information on our Investor Relations website at www.vita34group.com or you may send your questions to ir@vita34group.com.

7 RISKS AND MARKET OPPORTUNITIES

With regard to risks and market opportunities, there have been no significant changes to the risks and opportunities listed in the 2010 Annual Report at VITA 34 in Q2 2011.

INFORMATION AND KEY FIGURES ON THE SHARES

| | |
|--|---|
| Ticker symbol / Reuters symbol | V3V / V3VGn.DE |
| Securities number / ISIN | A0BL84 / DE000A0BL849 |
| Initial quotation | 03/27/2007 |
| Market segment | Prime Standard |
| Index | CDAX, Prime All Share, Technology All Share, Prime IG Biotechnology |
| Opening / High / Low / Closing price Q2 2011 (Xetra) | 5.00 EUR / 5.46 EUR / 3.69 EUR / 3.93 EUR |
| Number of shares issued | 2,646,500 |
| Freefloat as of 06/30/2011 | 48.8% |
| Market capitalization as of 06/30/2011 | EUR 10.4 million |
| Designated Sponsor | ICF Kursmakler AG |



8 OUTLOOK

In the further course of 2011 business development in Germany and the stable expansion of international activities for VITA 34 will continue to be a priority. At the end of the first half-year the company is represented in Germany, Austria, Switzerland, Spain, Italy, Slovenia and Slovakia, alone or via regional partners.

The careful expansion of the international presence to other regions is planned to be continued in the future. A particularly successful development is currently being demonstrated by our Italian partner Sorgente S.r.l. VITA 34 expects that this trend will continue in the further course of the year. In Spain, on the other hand, the market environment will remain challenging in the coming months. Here, the primary goal will be a stabilization of the storage figures at our subsidiary Secuvita, S. L., before growth can be taken on. The company in Slovenia is developing within the scope of expectations, in a market that is small with regard to births. The first umbilical cord blood storages will take place in the medium term via VITA 34 Slovakia and, thus, make a positive contribution to profits.

In Germany, the first positive effects from the adjusted marketing and sales activities should take hold in the second half-year. As of July 2011 the first marketing activities will be prepared and executed within the scope of cooperation agreement entered into with MVZ synlab Leverkusen GmbH as of the half-year. After a several month test phase in selected regions, the cooperation will be expanded. For the further course of 2011, additional applications of the umbilical cord blood stored at VITA 34 are expected within the context of therapies.

For the entire year 2011 VITA 34 expects revenues at least as high as those of the prior year and to be in the black.

9 DECLARATION OF THE LEGAL REPRESENTATIVES

We hereby affirm that to the best of our knowledge the consolidated financial statements provide a picture of the asset, financial and profit situation of the Group, which reflects the actual circumstances in accordance with the applicable accounting policies, and that the management report presents the course of business, including the financial results, and the situation of the Company in a manner that corresponds with the actual circumstances, and that the most important opportunities and risks of the foreseeable development of the Group have been described.

Leipzig, July 18, 2011

Management Board of VITA 34 International AG

Dr. med. Eberhard F. Lampeter

Jörg Ulbrich

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

06/30/2011

1 CONDENSED CONSOLIDATED STATEMENT OF INCOME

| EUR K | NOTE | 04/01/- 06/30/2011 | 04/01/- 06/30/2010 | 01/01/- 06/30/2011 | 01/01/- 06/30/2010 |
|--|------|-----------------------|-----------------------|-----------------------|-----------------------|
| Revenue | | 4,058 | 4,109 | 7,772 | 7,600 |
| Cost of sales | | -1,679 | -1,478 | -3,201 | -2,732 |
| Gross profit on sales | | 2,379 | 2,631 | 4,571 | 4,868 |
| Other operating income | | 17 | 275 | 227 | 512 |
| Selling expenses | | -1,790 | -1,909 | -3,691 | -3,567 |
| Administrative expenses | | -800 | -862 | -1,560 | -1,410 |
| Other operating expenses | | -24 | -111 | -175 | -219 |
| Net operating profit/loss | | -218 | 24 | -628 | 184 |
| Finance revenue | | 7 | 17 | 73 | 108 |
| Finance costs | | -56 | -40 | -111 | -76 |
| Earnings before taxes | | -267 | 1 | -666 | 216 |
| Income tax income/expense | 5 | 116 | -77 | 217 | -27 |
| Period result | | -151 | -76 | -449 | 189 |
| Period result attributable to | | | | | |
| Owners of the parent | | -137 | -22 | -425 | 243 |
| Non-controlling interests | | -14 | -54 | -24 | -54 |
| Earnings per share, basic / diluted (EUR) attributable to ordinary equity holders of the parent | | | | -0.16 | 0.09 |

2 CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

| EUR K | NOTE | 04/01/ 06/30/2011 | 04/01/ 06/30/2010 | 01/01/ 06/30/2011 | 01/01/ 06/30/2010 |
|--|------|----------------------|----------------------|----------------------|----------------------|
| Period result | | -151 | -76 | -449 | 189 |
| Changes recognized in other comprehensive income | | 0 | 0 | 0 | -3 |
| Changes recognized in profit or loss | | 0 | 0 | 0 | 4 |
| Difference from currency translation | | 0 | 0 | 0 | 1 |
| Changes recognized in other comprehensive income | | 0 | 0 | 0 | -19 |
| Changes recognized in profit or loss | | 0 | 0 | 0 | -110 |
| Gains/losses on available-for-sale financial assets | | 0 | 0 | 0 | -129 |
| Total comprehensive income for the year after tax | | -151 | -76 | -449 | 61 |
| Period result attributable to | | | | | |
| Owners of the parent | | -137 | -22 | -425 | 115 |
| Non-controlling interests | | -14 | -54 | -24 | -54 |

3 CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (ASSETS)

| EUR K | NOTE | 06/30/2011 | 12/31/2010 |
|-------------------------------|------|---------------|---------------|
| Non-current assets | | | |
| Goodwill | | 13,414 | 13,414 |
| Intangible assets | | 6,864 | 7,027 |
| Property, plant and equipment | | 3,929 | 3,767 |
| Other financial assets | | 85 | 125 |
| Non-current trade receivables | | 1,698 | 1,741 |
| Restricted Cash | | 413 | 475 |
| | | 26,403 | 26,549 |
| Current assets | | | |
| Inventories | | 568 | 626 |
| Trade receivables | | 2,900 | 2,914 |
| Other receivables and assets | | 1,241 | 1,412 |
| Short-term deposits | | 0 | 1,500 |
| Cash and cash equivalents | 4 | 2,444 | 3,687 |
| | | 7,153 | 10,139 |
| | | 33,556 | 36,688 |

3 CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (EQUITY AND LIABILITIES)

| EUR K | NOTE | 06/30/2011 | 12/31/2010 |
|--|------|---------------|---------------|
| Equity | | | |
| Issued capital | | 2,647 | 2,647 |
| Capital reserves | | 23,236 | 23,236 |
| Revenue reserves | | -7,393 | -6,968 |
| Treasury shares | | -436 | -436 |
| Non-controlling interests | | 315 | 339 |
| | | 18,369 | 18,818 |
| Non-current liabilities and deferred income | | | |
| Interest-bearing loans | | 2,313 | 1,760 |
| Silent partners' interests | | 949 | 940 |
| Deferred income taxes | | 731 | 948 |
| Deferred grants | | 873 | 929 |
| Deferred income | | 5,769 | 5,838 |
| | | 10,635 | 10,415 |
| Current liabilities and deferred income | | | |
| Trade payables | | 660 | 892 |
| Provisions | | 16 | 39 |
| Income tax liabilities | | 210 | 210 |
| Interest-bearing loans | | 1,121 | 2,060 |
| Deferred grants | | 102 | 102 |
| Other liabilities | | 931 | 3,079 |
| Deferred income | | 1,512 | 1,073 |
| | | 4,552 | 7,455 |
| | | 33,556 | 36,688 |

4 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN GROUP EQUITY

| EUR K | EQUITY ATTRIBUTABLE TO THE | | | |
|--|----------------------------|---------------------|---------------------|------------------------------------|
| | ISSUED CAPITAL | CAPITAL RESERVES | REVENUE RESERVES | CURRENCY TRANSLATION RESERVE |
| Balance as of January 1, 2010 | 2,647 | 23,236 | -7,138 | -1 |
| Period result | | | 243 | |
| Other result | | | | 1 |
| Comprehensive income | 0 | 0 | 243 | 1 |
| Changes in the consolidation scope | | | | |
| Changes from equity transactions | | | -310 | |
| Balance as of June 30, 2010 | 2,647 | 23,236 | 7,205 | 0 |
| Balance as of January 1, 2011 | 2,647 | 23,236 | -6,968 | 0 |
| Period result | | | -425 | |
| Other result | | | | |
| Comprehensive income | 0 | 0 | -425 | 0 |
| Balance as of June 30, 2011 | 2,647 | 23,236 | -7,393 | 0 |

| OWNERS OF THE PARENT | | | | | |
|----------------------|---------------------------|---------------------------|---------------------------------------|---------------------------|--------------|
| | AVAILABLE-FOR-SALE ASSETS | TOTAL SHAREHOLDERS EQUITY | TREASURY SHARES AT ACQUISITIONS COSTS | NON-CONTROLLING INTERESTS | TOTAL EQUITY |
| | 129 | 18,873 | 0 | 0 | 18,873 |
| | | 243 | | -54 | 189 |
| | -129 | -128 | | | -128 |
| | -129 | 115 | 0 | -54 | 61 |
| | | 0 | -436 | 1,933 | 1,497 |
| | | -310 | | -1,190 | -1,500 |
| | 0 | 18,678 | -436 | 689 | 18,931 |
| | 0 | 18,915 | -436 | 339 | 18,818 |
| | | -425 | | -24 | -449 |
| | | | | | 0 |
| | 0 | -425 | 0 | -24 | -449 |
| | 0 | 18,490 | -436 | 315 | 18,369 |

5 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

| EUR K | NOTE | 01/01/ 06/30/2011 | 01/01/ 06/30/2010 |
|--|------|----------------------|----------------------|
| Cash flow from operating activities | | | |
| Earnings before taxes | | -666 | 216 |
| Adjusted for: | | | |
| Amortization and depreciation | | 468 | 482 |
| Profit / loss from disposal of non-current assets | | 9 | 0 |
| Other non-cash expenses and income | | -71 | -20 |
| Exchange differences | | 0 | -6 |
| Finance revenues | | -73 | -108 |
| Finance expenses | | 111 | 76 |
| Cash flow from ordinary operations: | | | |
| +/- Trade receivables and other receivables and assets | | 268 | -134 |
| +/- Inventories | | 58 | -26 |
| +/- Trade payables and other liabilities | | -2,371 | -738 |
| +/- Provisions | | -23 | -142 |
| +/- Deferred income | | 370 | 168 |
| Interest paid | | -111 | -76 |
| Income taxes paid | | 0 | -1 |
| Cash flow from operating activities | | -2,031 | -309 |
| Cash flow from investing activities | | | |
| Purchase of intangible assets | | -181 | -304 |
| Purchase of property, plant and equipment | | -282 | -267 |
| Purchase of companies, net of assumed cash | | 0 | -4,154 |
| Proceeds from sale of property, plant and equipment | | 1 | 0 |
| Purchase of short-term investments | | 0 | -1,500 |
| Proceeds from sale of short-term investments | | 1,500 | 2,000 |
| Interest received | | 73 | 42 |
| Cash flow from investing activities | | 1,111 | -4,183 |

| EUR K | NOTE | 01/01/ 06/30/2011 | 01/01/ 06/30/2010 |
|---|----------|----------------------|----------------------|
| Cash flow from financing activities | | | |
| Changes in restricted cash | | 62 | 63 |
| Changes in loans | | -377 | 1,437 |
| Cash flow from financing activities | | -315 | 1,500 |
| Net change in cash and cash equivalents | | -1,235 | -2,992 |
| Cash and cash equivalents at the beginning of the reporting period | | 3,489 | 6,055 |
| Change in cash and cash equivalents from changes in the consolidation scope | | 0 | -38 |
| Net foreign exchange difference | | 0 | 2 |
| Cash and cash equivalents at the end of the reporting period | 4 | 2,254 | 3,027 |
| Short-term investments | | 0 | 1,500 |
| Liquid funds | | 2,254 | 4,527 |

NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 COMPANY INFORMATION

The parent VITA 34 International AG (the "Company") domiciled in Leipzig (Germany), at Deutscher Platz 5a, and filed in the register court of the Leipzig district court under HRB 20339 is a pure holding company and carries out management and financing functions for its subsidiaries. Its subsidiaries (together with the Company referred to as the "Group") operate in the field of cord blood storage. Their business purpose is to collect, process and store stem cells from cord blood and to develop cell therapeutics.

The unaudited, condensed, consolidated interim financial statements for the period from January 1 until June 30, 2011 were approved for publication by the Management Board on July 18, 2011.

2 ACCOUNTING AND VALUATION PRINCIPLES

2.1 Basis for the Preparation of the Financial Statements

The preparation of the consolidated interim financial statements for the period from January 1 until June 30, 2011 has been conducted in accordance with IAS 34 "Interim Financial Reporting".

The condensed consolidated interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the consolidated financial statements as of December 31, 2010.

2.2 Significant Accounting and Valuation Methods

The accounting and valuation methods used to prepare the condensed consolidated interim financial statements correspond with the methods used in the preparation of the consolidated financial statements for the fiscal year as of December 31, 2010.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2011:

- :: Changes to IAS 24: Related Party Disclosures
- :: Amendments to IAS 32: Financial Instruments – Presentation
- :: Changes to IFRIC 14: The Limit on a Defined benefit Asset, Minimum Funding Requirements and their Interaction
- :: IFRIC 19: Extinguishing Financial Liabilities with Equity Instruments
- :: Improvements to IFRS 2010

The standards and interpretations required to be used for the first time starting January 1, 2011 resulted in no significant effects on the interim financial statements of VITA 34 International AG.

3 CONSOLIDATION SCOPE

The consolidated interim financial statements encompass, apart from the parent company VITA 34 International AG, the interim financial statements of the following subsidiaries:

- :: VITA 34 AG, Leipzig, Germany,
- :: Novel Pharma, S. L., Alcala de Henares (Madrid), Spain,
- :: Secuvita, S. L., Madrid, Spain.

4 CASH AND CASH EQUIVALENTS

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

| CASH AND CASH EQUIVALENTS | 06/30/2011 | 06/30/2010 |
|----------------------------------|-------------------|-------------------|
| | EUR K | EUR K |
| Cash at banks and in hand | 2,444 | 3,180 |
| Current account overdrafts | -190 | -153 |
| | 2,254 | 3,027 |

5 INCOME TAXES

The major components of the income tax income listed in the condensed consolidated statement of income consist of the following:

| MAJOR COMPONENTS OF THE INCOME TAX INCOME | 01/01/-06/30/2011 | 01/01/-06/30/2010 |
|---|--------------------------|--------------------------|
| | EUR K | EUR K |
| CONSOLIDATED STATEMENT OF INCOME | | |
| Current income tax | | |
| Current income tax expense/income | 0 | -195 |
| Deferred income tax | | |
| Origination and reversal of temporary differences | 598 | 250 |
| On unused tax losses | -815 | -28 |
| Income tax income/expense | -217 | -27 |

6 SEGMENT REPORTING

Segment reporting has been done in accordance with the following geographical areas of activity:

:: Germany, Austria, Switzerland (DACH);

:: Spain.

Segment reporting according to products and services is not done, since the group deals exclusively with the storage of umbilical cord blood.

6.1 Information on geographical segments

The geographic segments of the group are determined in accordance with the revenues earned in the geographical areas.

The operating profit/loss of the business units is monitored by management separately, in order to make decisions concerning the distribution of resources and to determine the profitability of the units. The development of the segments is evaluated using the operating profit. The group financing (including finance revenues of EUR 73k and finance costs of EUR -111k) as well as taxes on income and profits, are taxed uniformly across the groups and are not attributed to the individual segments.

The offset prices between the operative segments are determined in accordance with typical market conditions amongst unrelated third-parties.

The following table contains information on sales revenues and segment results of the geographic segments of the group for the period from January 1 to June 30, 2011 and 2010:

| PERIOD FROM 01/01 – 06/30/2011 | DACH | SPAIN | TOTAL | CONSOLID- ATED | GROUP |
|--|--------------|--------------|--------------|-------------------|--------------|
| | EUR K | EUR K | EUR K | EUR K | EUR K |
| Income from transactions with external customers | 5,176 | 2,596 | 7,772 | 0 | 7,772 |
| Income from transactions with other segments | 751 | 0 | 751 | -751 | 0 |
| | 5,927 | 2,596 | 8,523 | -751 | 7,772 |
| EBIT (operating profit) | -291 | -337 | -628 | 0 | -628 |
| Depreciation | 276 | 192 | 468 | 0 | 468 |
| Segment assets | 33,335 | 10,255 | 43,590 | -10,034 | 33,556 |
| Segment liabilities | -13,742 | -11,479 | -25,221 | 10,034 | -15,187 |

| PERIOD FROM 01/01 – 06/30/2010 | DACH | SPAIN | TOTAL | CONSOLID- ATED | GROUP |
|--|--------------|------------|--------------|-------------------|--------------|
| | EUR K | EUR K | EUR K | EUR K | EUR K |
| Income from transactions with external customers | 6,739 | 861 | 7,600 | 0 | 7,600 |
| Income from transactions with other segments | 356 | 0 | 356 | -356 | 0 |
| | 7,095 | 861 | 7,956 | -356 | 7,600 |
| EBIT (operating profit) | 592 | -408 | 184 | 0 | 184 |
| Depreciation | -253 | -229 | -482 | 0 | -482 |
| Segment assets | 30,573 | 11,312 | 41,885 | -5,132 | 36,753 |
| Segment liabilities | -12,102 | -10,852 | -22,954 | 5,132 | -17,822 |

7 RELATED PARTY DISCLOSURES

The following table provides the total amount of transactions which have been entered into with related parties for the period from January 1 to June 30, 2011 and 2010:

| EXPENSES TO RELATED PARTIES | TOTAL AMOUNT OF TRANSACTIONS | |
|---|------------------------------|-------|
| | 2011 | 2010 |
| PERIOD FROM 01/01 – 06/30/ | EUR K | EUR K |
| Compensation of key management personnel of the Group: | | |
| Short-term benefits: | | |
| - Remuneration of the Supervisory Board | 9 | 15 |
| - Management Board salaries | 165 | 156 |

BOARD MEMBERS

SUPERVISORY BOARD

Dr.-Ing. Holger Födisch
Chairman

Managing Director Dr. Födisch Umweltmesstechnik AG

Richard J. Neeson
Deputy Chairman

President and Chief Executive Officer of AmeriHealth Administrators; President and Chief Executive Officer of Inter-Country Hospitalization Plan, Inc. and Inter-Country Health Plan, Inc. (Inter-Country)

Dr. med. Uwe Marx
Member of the Supervisory Board

Project Manager 'Multi-Organ-Chips' at TU Berlin and co-founder of VITA 34

MANAGEMENT BOARD

Dr. med. Eberhard F. Lampeter - CEO
Management Board of VITA 34 International AG

Responsible for Strategy, Production, Research and Development, Marketing and Sales as well as Investor Relations.

Dr. med. Lampeter founded the first private umbilical cord blood bank in Europe - VITA 34 in Leipzig - in 1997. He was Director of the Early Detection Center at the Diabetes Research Institute of the University of Duesseldorf from 1990 to 1997, following a previous position at the hospital in Munich-Schwabing. He has published some 50 scientific papers on diabetes, immunology and stem cell transplantation.

Dipl.-Wirtschaftsingenieur Jörg Ulbrich - CFO
Management Board of VITA 34 International AG

Responsible for Finance and Controlling, Administration and IT.

Jörg Ulbrich has been a member of the VITA 34 Management Board since 2009. Before that he was Commercial Director with procura power at VITA 34 AG for many years. He has worked for the company since 1997 and was significantly involved in building VITA 34.

FINANCIAL CALENDAR 2011

| | |
|-------------------|---|
| June 24, 2011 | Publication of Annual Report 2010 |
| June 18, 2011 | Publication of Q2 Report |
| May 11, 2011 | Munich Capital Market Conference |
| May 16, 2011 | Publication of Shareholders Letter [Aktionärsbrief] |
| July 12, 2011 | Annual General Meeting |
| July 18, 2011 | Publication of Q2 Report |
| October 17, 2011 | Publication of Q3 Report |
| November 22, 2011 | German Equity Forum |

CREDITS

Company Contact

Dr. med. Eberhard F. Lampeter
VITA 34 International AG
Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39
E-Mail: ir@vita34group.com

Contact for Press:

Axel Mühlhaus/ Dr. Sönke Knop
edicto GmbH
Eschersheimer Landstraße 42-44
60322 Frankfurt

Telephone: +49 69 905505-52
Fax: +49 69 905505-77
E-Mail: vita34@edicto.de

Copy and Editing

VITA 34 International AG, Leipzig
edicto GmbH, Frankfurt a. M.

Produktion

The production of the paper is certified in accordance with DIN ISO 9001, 14001 and OHSAS 18001. The cellulose and paper plants of the manufacturer are certified in accordance with FSC and PEFC Chain of Custody. The wood originated exclusively from controlled and sustainably managed forests.

Forward-looking statements

This Management Report contains statements and forecasts pertaining to the future development of VITA 34 International AG. These forecasts are estimates we made based on information that was available at the current time. Actual developments and currently expected results may vary in the event that assumptions that form the basis for the forecasts do not take place, or risks actually occur.

This Interim Report was published in German and English on July 18, 2011 and is available for download on our internet site.

VITA 34 on the Internet: www.vita34group.com

VITA 34 International AG

Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39

Internet: www.vita34group.com
E-Mail: ir@vita34group.com

